Immune Pharmaceuticals Inc represents a set of core values and a corporate philosophy that guide its operations. With a focus on innovation and excellence, the company strives to develop and deliver cutting-edge solutions in the field of biopharmaceuticals. Immune Pharmaceuticals Inc is committed to advancing the treatment of inflammatory and autoimmune diseases and improving patients' quality of life. By leveraging its expertise and resources, the company aims to address unmet medical needs and drive positive change in healthcare. Immune Pharmaceuticals Inc remains dedicated to fostering partnerships and collaborations to accelerate the development and commercialization of novel therapeutic options.

Immune Pharmaceuticals Inc is primarily present in the United States, with headquarters located in New York City. Additionally, the company has a strong presence in Israel, where its subsidiary, Immune Pharmaceuticals Ltd, is located.

Immune Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed phase 2 clinical trials for bertilimumab, its lead drug candidate for treating moderate-to-severe bullous pemphigoid. Immune Pharmaceuticals Inc also received orphan drug designations from the FDA for bertilimumab in both bullous pemphigoid and ulcerative colitis indications. Another notable achievement was the establishment of collaboration agreements with leading research institutions and pharmaceutical companies to further develop and commercialize bertilimumab. These milestones demonstrate Immune Pharmaceuticals Inc's commitment to advancing the treatment options for patients with serious autoimmune and inflammatory diseases.

Immune Pharmaceuticals Inc, a biopharmaceutical company, was founded in 2006 and is headquartered in New York City. The company focuses on developing and commercializing novel targeted therapeutics in the field of immuno-inflammatory diseases and cancer. Immune Pharmaceuticals Inc has a diverse pipeline of drug candidates targeting inflammatory diseases, dermatology, and oncology. Their drug candidates are designed to modulate the immune system and offer potential therapeutic benefits. The company has attracted attention and partnerships from leading pharmaceutical companies due to its innovative approach to treating various diseases. Immune Pharmaceuticals Inc has made significant progress in advancing its drug candidates through clinical trials, positioning itself as an emerging player in the biopharmaceutical industry.

Some of the main competitors of Immune Pharmaceuticals Inc in the market include [insert names of competitors here]. These companies also operate within the [mention the industry] industry and offer [explain the products or services offered by the competitors]. However, Immune Pharmaceuticals Inc distinguishes itself through [highlight the unique aspects or advantages of Immune Pharmaceuticals Inc]. With its [mention key strengths or offerings], Immune Pharmaceuticals Inc is well-positioned to maintain its competitive edge in the market.

Immune Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Immune Pharmaceuticals Inc focuses on developing and commercializing innovative therapeutic products in the field of immuno-dermatology and immuno-oncology. The company aims to address unmet medical needs in both areas through its drug candidates. Immune Pharmaceuticals Inc mainly focuses on obtaining and developing intellectual property rights for drug candidates, conducting clinical trials, and seeking collaborations or licensing deals for commercialization. Through its innovative approach, Immune Pharmaceuticals Inc strives to create value for its shareholders by bringing novel and effective treatments to patients suffering from dermatological and oncological conditions.

KGV untuk Immune Pharmaceuticals saat ini tidak dapat dihitung.

KUV untuk Immune Pharmaceuticals saat ini tidak dapat dihitung.

Skor Kualitas AlleAktien untuk Immune Pharmaceuticals adalah 2/10.

Pendapatan untuk Immune Pharmaceuticals saat ini tidak dapat dihitung.

Laba saat ini tidak bisa dihitung untuk Immune Pharmaceuticals.

Immune Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for inflammatory and immune diseases. The company was founded in 2006 and is headquartered in Englewood Cliffs, New Jersey. Immune Pharmaceuticals operates in three business segments: clinical research and development, immunotherapy, and dermatological therapy. The first business segment, clinical research and development, focuses on the discovery, development, and testing of new therapies. Immune Pharmaceuticals works closely with leading scientists and researchers to identify promising new therapies. Ongoing clinical trials include the investigation of Amiket, a pain and inflammation medication, as well as the development of new treatments for inflammatory diseases such as arthritis and psoriasis. The company plans to market these new therapies globally in the long term. The immunotherapy business segment is dedicated to developing therapies that utilize the body's immune system to treat diseases. The company is working on a new generation of immunotherapies specifically targeted at cancer. This includes a concept of drug delivery via liposomes, which aims to make cancer treatment more effective and tolerable. Immune Pharmaceuticals collaborates closely with leading research institutions and biotech companies to develop and bring these new immunotherapies to market. In the field of dermatological therapy, Immune Pharmaceuticals is developing medications to treat various skin conditions. The products include both prescription and over-the-counter medications for the treatment of skin conditions such as acne, eczema, psoriasis, and other inflammatory skin reactions. One of the company's key products in this area is AmiKet, a topical medication for pain and inflammation developed based on amitriptyline and ketamine. Immune Pharmaceuticals Inc adopts a differentiated business model and aims to integrate multiple aspects of drug development and marketing. The company relies on partnerships with top scientific institutions to develop innovative therapies and incorporate the latest research findings into its products. At the same time, Immune Pharmaceuticals has strong internal research expertise and clinical knowledge, allowing it to develop and test new therapies itself. Immune Pharmaceuticals is expanding internationally to market its innovative therapies worldwide. The company has activities in Europe, Israel, and Australia and is actively working to establish a presence in other regions. Immune Pharmaceuticals has strong partnerships with global pharmaceutical companies such as Merck and Teva, enabling it to distribute and sell its products worldwide. Immune Pharmaceuticals Inc is a dynamic biotech company that is developing a strong pipeline of innovative therapies to address the unmet need for new treatment options for inflammatory and immune diseases. With a differentiated business model based on internal capabilities and partnerships, as well as a global presence and strong distribution partners, the company has great potential to improve the lives of patients worldwide and create value for its investors.

Immune Pharmaceuticals membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk Immune Pharmaceuticals saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari Immune Pharmaceuticals adalah US45254C2008.

WKN dari Immune Pharmaceuticals adalah A2DQB0.

Ticker dari Immune Pharmaceuticals adalah IMNPQ.

Dalam 12 bulan terakhir, Immune Pharmaceuticals membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Immune Pharmaceuticals diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari Immune Pharmaceuticals saat ini adalah .

Immune Pharmaceuticals membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Immune Pharmaceuticals membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Immune Pharmaceuticals dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari Immune Pharmaceuticals tanggal 16/9/2024 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 16/9/2024.

Pembayaran dividen terakhir dilakukan pada 16/9/2024.

Pada tahun 2023, Immune Pharmaceuticals 0 USD telah dibayarkan sebagai dividen.

Dividen dari Immune Pharmaceuticals dibayarkan dalam USD.